AbCellera Biologics (NASDAQ:ABCL - Get Free Report) is projected to release its Q4 2024 earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.58 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.
AbCellera Biologics Trading Down 11.3 %
Shares of ABCL traded down $0.33 during midday trading on Friday, reaching $2.59. The stock had a trading volume of 9,923,651 shares, compared to its average volume of 4,236,253. The firm has a market cap of $765.01 million, a PE ratio of -4.25 and a beta of 0.42. The firm has a 50 day simple moving average of $3.10 and a 200-day simple moving average of $2.84. AbCellera Biologics has a one year low of $2.31 and a one year high of $5.26.
Analysts Set New Price Targets
A number of equities analysts have weighed in on ABCL shares. Benchmark reissued a "hold" rating on shares of AbCellera Biologics in a research report on Tuesday, November 5th. Stifel Nicolaus decreased their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday. Finally, KeyCorp dropped their price target on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th.
Get Our Latest Report on AbCellera Biologics
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Featured Articles
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
